News Releases
All Releases
View Summary Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
Aug 11, 2008
PDF 11.0 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
Jul 23, 2008
PDF 10.2 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
Jul 14, 2008
PDF 20.6 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals to Report Fiscal Year 2008 Financial Results
Jul 9, 2008
PDF 7.8 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
Jul 2, 2008
PDF 11.3 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
Jul 1, 2008
PDF 12.3 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
Jun 30, 2008
PDF 10.9 KB Add to Briefcase
View Summary DSM and Crucell Sign Agreement with Avid Bioservices to Serve as First Pre-Approved U.S. Contract Manufacturer of PER.C6 ® Cell Line Proteins
Jun 25, 2008
PDF 12.2 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
Jun 16, 2008
PDF 10.5 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
Jun 2, 2008
PDF 11.8 KB Add to Briefcase
View Summary Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer
May 31, 2008
PDF 12.3 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports Studies Published in 'Science' Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
May 13, 2008
PDF 12.6 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer Trial
Apr 29, 2008
PDF 10.8 KB Add to Briefcase
View Summary Peregrine Researchers Present New Preclinical Data at AACR Annual Meeting Confirming Unique Anti-Tumor Mechanism of Bavituximab
Apr 15, 2008
PDF 11.4 KB Add to Briefcase
View Summary Preclinical Study Presented at AACR Annual Meeting Shows Peregrine's Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
Apr 15, 2008
PDF 11.8 KB Add to Briefcase
View Summary Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
Apr 15, 2008
PDF 12.2 KB Add to Briefcase
View Summary Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies
Apr 14, 2008
PDF 11.5 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
Apr 11, 2008
PDF 8.7 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Mar 11, 2008
PDF 19.6 KB Add to Briefcase
View Summary Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
Mar 11, 2008
PDF 12.3 KB Add to Briefcase
Showing 141-160 of 436 Page: 1 ... 4 5 6 7 8 9 10 11 12 ... 22 Previous 20 | Next 20
Add to Briefcase = add release to Briefcase
Print E-mail